ST
RPRX icon

Smithfield Trust’s Royalty Pharma RPRX Stock Holding History

Smithfield Trust’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33K Sell
592
-11
-2% -$573 ﹤0.01% 689
2026
Q1 		$28K Hold
603
– – ﹤0.01% 701
2025
Q4 		$23K Sell
603
-7
-1% -$267 ﹤0.01% 733
2025
Q3 		$21K Buy
+610
New +$22.1K ﹤0.01% 735

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smithfield Trust's RPRX Position: Q2 2026 in Review

Smithfield Trust reduced its Royalty Pharma (RPRX) stake by 1.8% in Q2 2026, selling an estimated $573 and leaving 592 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #689.

Smithfield Trust first reported a position in RPRX in Q3 2025 and has held it in 4 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Smithfield Trust held 592 shares of Royalty Pharma worth $33K as of Q2 2026.
  • Smithfield Trust sold 11 Royalty Pharma shares in Q2 2026, an estimated $573.
  • Royalty Pharma made up ﹤0.01% of Smithfield Trust's portfolio in Q2 2026, its #689 holding.
  • Smithfield Trust first reported a position in Royalty Pharma in Q3 2025 and has held it in 4 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Smithfield Trust's 13F filing for Q2 2026, filed 5 Aug 2026.